Skip to main content
. 2021 Mar 23;16(3):e0249049. doi: 10.1371/journal.pone.0249049

Fig 6. Phenotypic evaluation of ex vivo GSK2618960-treated PBMC.

Fig 6

PBMC from healthy donors were treated with either Fc control anti-beta amyloid antibody or GSK2618960 for 7 days. (A). Increased DC subsets (CD3-, HLA-DR+, CD11c+) in GSK2618960 treatment. (B). Average % DC subset in medium, Fc control or GSK2618960 treatment from three healthy donors (error bars represent the standard deviation of replicate treatment). Statistical comparison test results: ‘ns’ = not statistically significant (p-value ≥ 0.050); ‘*’ = p-value < 0.050; ‘**’ = p-value < 0.010; ‘***’ = p-value < 0.001. (C). Increased expression of CD86, CD209, CD40, and CD83 on DCs in GSK2618960 treatment.